Merck KGaA's (MKGAY) "Neutral" Rating Reaffirmed at Goldman Sachs


's stock had its "neutral" rating reissued by research analysts at Goldman Sachs in a note issued to investors on Saturday, AnalystRatings.Net reports. They currently have a $56.00 target price on the stock, down from their previous target price of $60.00.



from Biotech News